Wesfarmers shares hit as Target misses mark

Wesfarmers shares suffered their biggest fall in almost two years after the company sharply lowered Target's earnings forecast.

Wesfarmers shares suffered their biggest fall in almost two years after the company sharply lowered Target's earnings forecast.

The retail conglomerate said on Friday that Target's profits had been hit by a late start to winter, the clearing of excess stocks, shoplifting and restructuring costs.

The discount department store is now expected to report earnings before interest and tax for the 2013 financial year of between $140 million and $160 million, more than 40 per cent below the $244 million reported in the previous year.

"I don't think we would be particularly surprised that earnings are weak, but the size of the downgrade is probably a bit more than most of us were expecting," National Australia Bank analyst Michael Bush said.

"Target has been struggling for several years, partly a function of the broader consumer environment and some other Target-specific [issues]."

Wesfarmers shares closed 2.87 per cent lower at $42.93.

Managing director Richard Goyder said the earnings were "disappointing" but the retail chain would work on keeping Target competitive and maintaining its brand.

Target has performed poorly compared with its peers Kmart, which is also owned by Wesfarmers, and Big W and has battled excess inventory and soft consumer sentiment.

Last month, the head of operations at the Coles supermarkets chain, Stuart Machin, replaced Dene Rogers as Target's managing director. Mr Rogers resigned only 18 months after taking on the role.

The Target announcement also pushed other retail stocks lower. The Reject Shop slipped 3.3 per cent, JB Hi-Fi dropped 2.9 per cent and Woolworths shrank 0.9 per cent.

The profit downgrade came as Australian Pharmaceutical Industries (API) chief executive Stephen Roche said he could not see the retail sector improving for at least another two to three years.

API has turned its focus away from wholesale drug delivery to health and beauty through its Priceline retail business.

Mr Roche said at an American Chamber of Commerce lunch on Friday that he expected consumer sentiment to remain fragile.

"I can't see any systemic change in consumer behaviour for at least two to three years and the consequence of that is ... we've got to learn and be good at operating in a very subdued and weak consumer environment," he said.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Join the Conversation...

There are comments posted so far.

If you'd like to join this conversation, please login or sign up here

Related Articles